Compounding Pharmacies' Lawsuit Against FDA Will Continue - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compounding Pharmacies' Lawsuit Against FDA Will Continue

Pharmaceutical Technology

Compounding Pharmacies' Lawsuit Against FDA Will Continue

The US District Court for the Western District of Texas (Midland, TX) has ruled that a lawsuit against the US Food and Drug Administration will proceed, despite a request from FDA to drop the case.

A coalition of 10 compounding pharmacies hit FDA with a lawsuit for engaging in “unlawful” inspections of state-regulated pharmacies. At the center of the lawsuit is FDA’s 2003 compliance policy guideline (CPG 7125.40), which prohibits the compounding of drugs from bulk ingredients.  The agency has since inspected several compounding pharmacies to enforce the guidelines.

The pharmacies petitioned the court to allow them to continue using compounding methods without FDA considering them a manufacturer or requiring them to meet the agency’s manufacturing guidelines. The coalition alleges that federal law prohibits FDA from inspecting state-regulated pharmacies and that the agency is exercising jurisdiction without the authority to do so.

–Kaylynn Chiarello

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here